Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Bovine, Dog, Human, Mouse, Pig, Rat|
|Published species reactivity||Rat, Mouse, Human, Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide corresponding to residues C G G N(387) I T E G E(392) of human aggrecan.|
|Storage buffer||PBS with 1mg/ml BSA|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||Assay dependent|
|Western Blot (WB)||1 ug/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-1746 detects human, rat, mouse, bovine, canine, and porcine aggrecan neo G1.
PA1-1746 has been successfully used in Western blot and immunofluorescence procedures. By Western blot, this antibody detects an ~64 kDa protein representing the neoepitope sequence (NITEGE) generated by aggrecanase-mediated cleavage at Glu373-Ala374 of aggrecan core proteins.
The PA1-1746 immunogen is a synthetic peptide corresponding to residues residues C G G N(387) I T E G E(392) of human aggrecan.
Aggrecan is a member of large, aggregating proteoglycans (also including, versican, brevican and neurocan) found in articular cartilage. Aggrecan is composed of three major domains: G1, G2, and G3. Between the G1 and G2 domains there is an interglobulin region (IGD). The IGD region is the major site of cleavage by specific proteases like metalloproteinases (MMP and quote;s) and aggrecanase (ADAMTS). Aggrecan cleavage has been associated with a number of degenerative diseases including rheumatoid arthritis and osteoarthritis.
The C-terminal NITEGE fragment is one of the G1 fragments produced when aggrecan is cleaved with aggrecanase. It is the most abundant fragment found in normal human synovial fluid and articular cartilage, and is the major product produced by aggrecanase cleavage. The NITEGE fragment has also been shown to accumulate rapidly after an acute cartilage injury.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Brief Report: JNK-2 Controls Aggrecan Degradation in Murine Articular Cartilage and the Development of Experimental Osteoarthritis.
PA1-1746 was used in immunohistochemistry - paraffin section to analyze development of experimental osteoarthritis and aggrecan degradation in murine articular cartilage by JNK-2
|Ismail HM,Miotla-Zarebska J,Troeberg L,Tang X,Stott B,Yamamoto K,Nagase H,Fosang AJ,Vincent TL,Saklatvala J||Arthritis and rheumatology (Hoboken, N.J.) (68:1165)||2016|
Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo.
PA1-1746 was used in immunohistochemistry to study EGFR-mediated anabolic signaling in articular cartilage using Mig6 conditional knockout mice
|Shepard JB,Jeong JW,Maihle NJ,O'Brien S,Dealy CN||Arthritis research and therapy (15:null)||2014|
Transcription factor Nfat1 deficiency causes osteoarthritis through dysfunction of adult articular chondrocytes.
PA1-1746 was used in immunohistochemistry to study the role of transcription factor NFAT1 in osteoarthritis and its mechanism
|Wang J,Gardner BM,Lu Q,Rodova M,Woodbury BG,Yost JG,Roby KF,Pinson DM,Tawfik O,Anderson HC||The Journal of pathology (219:163)||2009|
Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo.
PA1-1746 was used in western blot to investigate the effect of ADAMTS activities and MMP-like activities on cartilage matrix
|Sandy JD,Verscharen C||The Biochemical journal (358:615)||2001|
The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1.
PA1-1746 was used in western blot to investigate the degradation products of aggrecan by aggrecanase in interleukin 1-treated rat chondrosarcoma cells
|Sandy JD,Thompson V,Doege K,Verscharen C||The Biochemical journal (351:161)||2000|
AGC1; AGCAN; aggrecan 1; aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal antibody A0122); Aggrecan core protein; aggrecan epidermal growth factor-like domain-1; aggrecan, structural proteoglycan of cartilage; cartilage aggregating proteoglycan; Cartilage-specific proteoglycan core protein; chondroitin sulfate proteoglycan 1; chondroitin sulfate proteoglycan core protein 1; CSPCP; CSPG1; CSPGCP; large aggregating proteoglycan; large aggregating proteoglycan, antigen; MSK16; SEDK
ACAN; Agc; AGC1; AGCAN; b2b183Clo; BOS_20116; cmd; CSPCP; CSPG1; CSPGCP; MSK16; SEDK